A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

NCT02262741 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL: MEDI4736
BIOLOGICAL: tremelimumab

Sponsor

MedImmune LLC